PLA2G4A and breast carcinoma: Altogether, this study identifies S1007/cPLA2 signaling as a promising target against metastatic breast cancers and demonstrates the efficacy of pharmacological inhibition of cPLA2 to improve the clinical outcome of S100A7-overexpressing breast cancer patients.